

Charles Khouri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428328/publications.pdf>

Version: 2024-02-01

44
papers

808
citations

623188

14
h-index

580395

25
g-index

49
all docs

49
docs citations

49
times ranked

925
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Facial Paralysis With mRNA COVID-19 Vaccines. <i>JAMA Internal Medicine</i> , 2021, 181, 1243.	2.6	88
2	SGLT2 inhibitors and the risk of lower-limb amputation: Is this a class effect?. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1531-1534.	2.2	75
3	The French health pass holds lessons for mandatory COVID-19 vaccination. <i>Nature Medicine</i> , 2022, 28, 232-235.	15.2	73
4	Drug-induced Raynaud's phenomenon: beyond Î²-adrenoceptor blockers. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 6-16.	1.1	55
5	Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 512-523.	4.0	47
6	Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. <i>Journal of Clinical Epidemiology</i> , 2021, 134, 14-21.	2.4	42
7	Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: An effect size meta-analysis. <i>Wound Repair and Regeneration</i> , 2017, 25, 883-891.	1.5	37
8	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. <i>European Respiratory Journal</i> , 2019, 53, 1802472.	3.1	37
9	On-Demand Sildenafil as a Treatment for Raynaud Phenomenon. <i>Annals of Internal Medicine</i> , 2018, 169, 694.	2.0	26
10	Intermittent hypoxia-related alterations in vascular structure and function: a systematic review and meta-analysis of rodent data. <i>European Respiratory Journal</i> , 2022, 59, 2100866.	3.1	21
11	Peripheral vasoconstriction induced by Î²-adrenoceptor blockers: a systematic review and a network meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 549-560.	1.1	19
12	Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. <i>Annals of Internal Medicine</i> , 2021, 174, 878-880.	2.0	19
13	Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances. <i>Frontiers in Pharmacology</i> , 2021, 12, 668765.	1.6	19
14	High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 73-79.	2.4	19
15	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. <i>Chest</i> , 2018, 154, 136-147.	0.4	18
16	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e237-e246.	2.2	18
17	Cardiac consequences of intermittent hypoxia: a matter of dose? A systematic review and meta-analysis in rodents. <i>European Respiratory Review</i> , 2022, 31, 210269.	3.0	18
18	A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. <i>Journal of Clinical Epidemiology</i> , 2021, 139, 191-198.	2.4	16

#	ARTICLE	IF	CITATIONS
19	Adenovirus <scp>COVID-19</scp> Vaccines and Guillain-Barré Syndrome with Facial Paralysis. <i>Annals of Neurology</i> , 2022, 91, 162-163.	2.8	15
20	Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data. <i>Journal of Clinical Medicine</i> , 2021, 10, 2089.	1.0	14
21	Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, e103-e105.	0.7	12
22	Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2406-2408.e1.	2.0	10
23	Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2217-2222.	1.1	9
24	Impact of the French Levothyrox crisis on signal detection in the World Health Organization pharmacovigilance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1427-1428.	0.9	8
25	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1306-1315.	1.5	8
26	Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3535-3536.	1.1	8
27	Fluoxetine and Raynaud's phenomenon: friend or foe?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2307-2309.	1.1	7
28	Safety Profile of Sclerosing Agents. <i>Dermatologic Surgery</i> , 2019, 45, 1517-1528.	0.4	7
29	Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5227-5237.	1.1	7
30	French translation and linguistic validation of the Raynaud's condition score. <i>Thérapie</i> , 2019, 74, 627-631.	0.6	6
31	Adverse event reporting and Bell's palsy risk after COVID-19 vaccination. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1490-1491.	4.6	6
32	Severe central sleep apnoea associated with nalmefene: a case report. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1075-1076.	1.1	5
33	Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 229-232.	0.6	5
34	Investigating the association between ALK Receptor Tyrosine Kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. <i>European Respiratory Journal</i> , 2021, 58, 2101576.	3.1	5
35	Skin necrosis and calcifications after extravasation of vancomycin: a localised form of calciphylaxis?. <i>Journal of Wound Care</i> , 2021, 30, 390-393.	0.5	4
36	Implantable cardiac devices in sleep apnoea diagnosis: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2022, 348, 76-82.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Proton pump inhibitors and Raynaud's phenomenon: is there a link?. British Journal of Clinical Pharmacology, 2018, 84, 2443-2444.	1.1	2
38	Impact of Bariatric Surgery on Medication Efficacy: an Analysis of World Health Organization Pharmacovigilance Data. Obesity Surgery, 2021, 31, 2823-2830.	1.1	1
39	Gout and Levodopa: An unknown adverse effect?. Fundamental and Clinical Pharmacology, 2022, 36, 221-223.	1.0	1
40	Caution in Interpreting Facial Paralysis Data to Understand COVID-19 Vaccination Risks—Reply. JAMA Internal Medicine, 2021, 181, 1420-1421.	2.6	1
41	Impact of global warming on Raynaud's phenomenon: a modelling study. F1000Research, 2020, 9, 829.	0.8	1
42	Pharmacology and pharmacovigilance of protein kinase inhibitors. Therapie, 2021, , .	0.6	1
43	Triptans and SCAD. Journal of the American College of Cardiology, 2021, 78, 2129-2130.	1.2	1
44	Treatment efficacy in secondary Raynaud's phenomenon — Authors' reply. Lancet Rheumatology, The, 2020, 2, e132-e133.	2.2	0